Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acad Pediatr ; 23(5): 947-951, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-36441091

RESUMO

OBJECTIVE: Outpatient management of pediatric obesity can be difficult, requiring a significant time commitment from both provider and patient. Multidisciplinary clinic-based programs have shown promising effects in reducing BMI during intervention, but whether these changes are sustained over time is not well studied. The purpose of this study was to determine the post-treatment outcomes of children seen in a multidisciplinary pediatric obesity clinic (MPOC). METHODS: A retrospective chart review was performed using the MPOC database, which included all clinic patients from January 2008 to August 2016 who attended a minimum of 2 visits (n = 472). The primary outcome was the absolute change in BMI Z-score (BMIZ) from the final intervention visit compared to 1- and 2-years post-intervention. Multivariate regression analysis was performed to characterize predictors of change in BMIZ. RESULTS: MPOC patients ranged in age from 3 to 18 years. Mean BMIZ decreased significantly during intervention (-0.13 ± 1.47, P < .001) and was maintained at 1- and 2-years post-intervention. In participants ages 3 to 5, BMIZ further decreased at 1 year post intervention (-0.27 ± 0.26, P < .001). Age at time of referral was the only significant predictor of change in BMIZ. CONCLUSIONS: Outpatient, multidisciplinary intervention for pediatric obesity was effective in reducing or stabilizing BMIZ during and beyond the intervention, particularly when patients were referred at an early age. Although primary prevention is the ideal management, multidisciplinary clinic intervention can be effective in the sustained treatment of pediatric obesity.


Assuntos
Obesidade Infantil , Criança , Humanos , Pré-Escolar , Adolescente , Obesidade Infantil/prevenção & controle , Índice de Massa Corporal , Estudos Retrospectivos , Resultado do Tratamento , Instituições de Assistência Ambulatorial
2.
WMJ ; 121(1): 61-63, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35442582

RESUMO

INTRODUCTION: Laboratory investigations pursued for infants with failure to thrive (FTT) often show mild transaminase elevations, the incidence and significance of which are unknown. METHODS: This retrospective chart review included infants diagnosed with simple nutritional FTT at a single academic tertiary care system. Comparisons of diagnostic studies and outcomes between children with and without transaminase elevation were performed using chi-square and Wilcoxon rank sum tests. RESULTS: None of the infants with abnormal transaminases required additional follow-up or developed alternative diagnoses in the following year. DISCUSSION: Transaminase elevation may be common in infants with FTT and may not warrant further investigation if the history indicates an isolated etiology of insufficient nutrition.


Assuntos
Insuficiência de Crescimento , Transaminases , Criança , Insuficiência de Crescimento/diagnóstico , Insuficiência de Crescimento/epidemiologia , Insuficiência de Crescimento/etiologia , Humanos , Incidência , Lactente , Estudos Retrospectivos
3.
Cancer Biol Ther ; 16(10): 1430-3, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26176686

RESUMO

Anaplastic thyroid carcinoma (ATC) is a rare, poorly differentiated type of thyroid cancer occurring in less than 5% of all thyroid cancers. Patients typically have a poor prognosis with very few options for treatment. (2) With current therapy of surgery, chemotherapy, and radiation, median survival is only 6 months from the time of diagnosis. Several mutations in cell cycle regulation have been discovered in ATC that contribute to its undifferentiated state, one of which is the BRAF kinase mutation. This mutation results in activation of the MAPK pathway and uncontrolled cell proliferation. In this case report, a 51 y old male presented with a 2-week history of hoarseness and was diagnosed with ATC. Genetic analysis revealed a mutation in BRAF kinase; the patient subsequently began therapy with vemurafenib, a BRAF kinase inhibitor indicated for melanoma. After an initial response, the patient quickly declined and consequently died from his disease. Anaplastic thyroid carcinoma is a deadly cancer without an effective treatment. Inhibiting mutated enzymes that drive the development of this cancer is a potential drug target that may improve outcomes in patients with ATC.


Assuntos
Indóis/uso terapêutico , Sulfonamidas/uso terapêutico , Carcinoma Anaplásico da Tireoide/tratamento farmacológico , Humanos , Indóis/administração & dosagem , Masculino , Pessoa de Meia-Idade , Sulfonamidas/administração & dosagem , Carcinoma Anaplásico da Tireoide/patologia , Vemurafenib
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...